Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group-Reference-Cited by-同舟云学术

Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group

Published:2012-03 Issue:1 Volume:10 Page:120-127
ISSN:1359-6349
Container-title:European Journal of Cancer Supplements
language:en
Short-container-title:European Journal of Cancer Supplements

Author:

Daidone Maria Grazia,Foekens John A.,Harbeck Nadia,Martens John,Brunner Nils,Thomssen Christoph,Hall Jacqueline A.,Salgado Roberto,Dittmer Juergen,Geurts-Moespot Anneke,Duffy M. Joe,Sweep Fred C.G.J.,Schmitt Manfred

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference48 articles.

1. The molecular pathology of cancer;Harris;Nat Rev Clin Oncol,2010

2. Integration of translational research in the European Organization for Research and Treatment of Cancer Research (EORTC) Clinical Trial Cooperative Group mechanisms;Lehmann;J Transl Med,2003

3. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers;Hayes;J Natl Cancer Inst,1996

4. Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1;Schmitt;Expert Rev Mol Diagn 2,2011

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. T-cell acute lymphoblastic leukemia from miRNA perspective: Basic concepts, experimental approaches, and potential biomarkers;Blood Reviews;2018-11

2. A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours;British Journal of Cancer;2014-10-07

3. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies;Breast Cancer Research;2014-08